相关实验视频

Updated: Sep 20, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

多发性硬化症患者的痴呆症:系统性审查和元分析

Omid Mirmosayyeb^1,2, Danial Dehghani Firouzabadi³, Soroush Oraee⁴

¹Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Brain and behavior

|May 30, 2025

概括

患有多发性硬化症 (MS) 的人患痴呆症的风险高出1.67倍. 虽然不常见,但MS中痴呆的患病率为5.31%,需要进一步研究.

科学领域:

神经学神经学
神经免疫学神经免疫学
认知科学认知科学

背景情况:

多发性硬化症 (MS) 是一种影响中枢神经系统的自身免疫性疾病.
认知功能障碍是MS的已知并发症,与痴呆症有潜在的联系.
在MS中痴呆的确切机制和患病率尚不清楚.

研究的目的:

确定MS (PwMS) 患者痴呆症的综合流行率.
评估PwMS中痴呆的综合风险 (危险比率).
在多发性硬化症的背景下对痴呆症的现有证据进行综合.

主要方法:

一个系统的元分析,遵循PRISMA指南.
在Embase,PubMed,Web of Science和Scopus数据库中进行全面的文献搜索.
将报告痴呆症流行率或危险比率的观察性研究纳入PwMS.
随机效应模型用于计算聚合的流行率和危险率.

主要成果:

在37831名多发性硬化症患者中,痴呆的综合流行率为5.31% (95% CI:2.25%-11.98%).
聚合危险比率为1.67 (p < 0.01),表明PwMS患者的痴呆风险显著增加.
在流行率和风险估计中观察到高异质性 (I2>70%).

结论:

痴呆症在MS中并不常见,但与普通人群相比,PwMS面临的风险明显增加.
研究中的显著异质性表明,在解释聚合估计时要谨慎.
需要进一步的研究来验证这些发现,并探索潜在的机制.

关键词:

阿尔茨海默病的疾病阿尔茨海默病的疾病.痴呆症痴呆症是一种痴呆症.多发性硬化症多发性硬化症

更多相关视频

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Using Retinal Imaging to Study Dementia

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

相关概念视频

Dementia

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...